

2

AD-201 097

AD _____

AD-A201 097

GENETIC ENGINEERING OF
CLOSTRIDIUM DIFFICILE TOXIN A VACCINE

ANNUAL REPORT

Lycurgus L. Muldrow
Joe Johnson

July 14, 1988

Supported by
U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
FORT DETRICK, FREDERICK, MARYLAND 21701-5012

Contract No. DAMD17-87-C-7135

Spelman College
Atlanta, Georgia 30314

Approved for public release; distribution unlimited.

The finding in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

DTIC
SELECTE
NOV 01 1988
S H D

88 11 01 026

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified		1b. RESTRICTIVE MARKINGS										
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release; distribution unlimited										
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE												
4. PERFORMING ORGANIZATION REPORT NUMBER(S)		5. MONITORING ORGANIZATION REPORT NUMBER(S)										
6a. NAME OF PERFORMING ORGANIZATION Spelman College	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MONITORING ORGANIZATION										
6c. ADDRESS (City, State, and ZIP Code) Atlanta, Georgia 30314		7b. ADDRESS (City, State, and ZIP Code)										
8a. NAME OF FUNDING / SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command	8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-87-C-7135										
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012		10. SOURCE OF FUNDING NUMBERS <table border="1" style="width:100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width:25%;">PROGRAM ELEMENT NO.</td> <td style="width:25%;">PROJECT NO.</td> <td style="width:25%;">TASK NO.</td> <td style="width:25%;">WORK UNIT ACCESSION NO.</td> </tr> <tr> <td>62770A</td> <td>3M1-62770A871</td> <td>AA</td> <td>348</td> </tr> </table>		PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO.	62770A	3M1-62770A871	AA	348	
PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO.									
62770A	3M1-62770A871	AA	348									
11. TITLE (Include Security Classification) (U) Genetic Engineering of <u>Clostridium difficile</u> Toxin A Vaccine												
12. PERSONAL AUTHOR(S) Lycurgus L. Muldrow and Joe Johnson												
13a. TYPE OF REPORT Annual	13b. TIME COVERED FROM 6/15/87 TO 6/14/88	14. DATE OF REPORT (Year, Month, Day) 1988 July 14	15. PAGE COUNT 22									
16. SUPPLEMENTARY NOTATION												
17. COSATI CODES <table border="1" style="width:100%; border-collapse: collapse; margin-top: 5px;"> <thead> <tr> <th style="width:33%;">FIELD</th> <th style="width:33%;">GROUP</th> <th style="width:33%;">SUB-GROUP</th> </tr> </thead> <tbody> <tr> <td>06</td> <td>02</td> <td></td> </tr> <tr> <td>06</td> <td>03</td> <td></td> </tr> </tbody> </table>		FIELD	GROUP	SUB-GROUP	06	02		06	03		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) <u>Clostridium difficile</u> Vaccine Recombinant DNA RA 1	
FIELD	GROUP	SUB-GROUP										
06	02											
06	03											
19. ABSTRACT (Continue on reverse if necessary and identify by block number) The major long range objective of this project is to use <u>C. difficile</u> toxin A as a model to add technical information in the area of vaccine biotechnology as it relates to recombinant DNA studies. However, prior to accomplishing this goal <u>C. difficile</u> toxin A DNA must be cloned, sequenced and characterized, which was the objective of the first year of work, and is reported in part in this document.												
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION Unclassified										
22a. NAME OF RESPONSIBLE INDIVIDUAL Mary Frances Bostian		22b. TELEPHONE (Include Area Code) 301-663-7325	22c. OFFICE SYMBOL SGRD-RMI-S									

SUMMARY

Recombinant DNA technology allows for an approach to subunit vaccine production that should provide advantages over existing techniques. Improvement of vaccine biotechnology in the area of recombinant DNA studies using Clostridium difficile toxin A as the model, is the major long range objective of this project. However, prior to accomplishing this goal C. difficile toxin genes must be cloned, sequenced and characterized, which was the objective of the first year of work, and is reported in part in this document. A genomic library in lambda gt11 of C. difficile chromosomal DNA was screened using anti-toxin A which resulted in the identification of one stable positive clone, lambda cd19. Verification of the immunological identity of the isolated toxin A gene fragment in lambda cd19 was determined by affinity purifying toxin A antibodies specific for lambda cd19 gene product, and using these selected antibodies to probe a Western blot of purified toxin A. The insert in lambda cd19 was demonstrated to be a 0.3 kb fragment by restriction digestion, and by hybridization of the clone to a chromosomal digest of C. difficile. The peptide coded for by the toxin A gene fragment in lambda cd19 was not cytotoxic for 3T3 mammalian tissue culture cells. Sequence analysis of DNA encoding for toxin A was determined using the Sanger chain-termination sequence procedure. The amino acid sequence was deduced for the DNA sequence and a hydropathy plot of the open reading frame given. Future studies within the next year will be centered around sequencing the entire toxin A gene and predicting epitopes. /

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
ERIC	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

The investigator(s) have abided by the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (April 1982) and the Administration Practices Supplements.

TABLE OF CONTENTS

	Page
Background	4
Materials and Methods	6
Results and Discussion	8
Recommendations and Conclusions	9
References	10
Figures	
Figure 1. Purity of toxin A, and confirmation of cloned toxin determinants.	13
Figure 2. Restriction digestion of lambda gt11 and lambda cd19.	14
Figure 3. Southern hybridization of restriction digested <u>C.</u> <u>difficile</u> chromosomal DNA with [alpha- ³² P] dCTP labeled lambda cd19.	15
Figure 4. Restriction digestion of cdmp19.	16
Figure 5. Restriction map of the <u>Kpn1-Sac1</u> DNA fragment from lambda cd19 that was subcloned into M13.	17
Figure 6. DNA and amino acid sequence of toxin A gene fragment.	18
Figure 7. Hydropathy plot of recombinant peptide.	19

BACKGROUND

Recombinant DNA technology allows for an approach to subunit vaccine production that should provide advantages over existing techniques. Potential advantages of genetically engineered antigens for the preparation of vaccines are stability, purity, safety of preparation, price, lack of side effects and variety of serotypes. A number of determinants coding for antigens have been cloned from viruses, bacteria, parasites and toxins, with the ultimate goal of producing better vaccines and improving molecular techniques for the development of vaccines. Improvement of vaccine biotechnology in the area of recombinant DNA studies using Clostridium difficile toxin A as the model, is the major long range objective of this project. However, prior to accomplishing this goal C. difficile toxin genes must be cloned, sequenced and characterized, which was the objective of the first year of work, and is reported in part in this document.

1. Clostridium Difficile Toxin A Literature Review

C. difficile was first described in 1935 (1), but has only been recognized as a clinically significant pathogen within the last decade. This toxin producing strict anaerobic bacterium is the causative agent for the diarrheal syndrome termed antibiotic associated pseudomembranous colitis (PMC) (2,3,4,5). PMC is a disease of the lower gastrointestinal tract that can be histopathologically characterized by exudative plaques on the bowel mucosa. Pathogenicity and cytotoxicity associated with PMC has been linked to production of two toxins, A (enterotoxin) and B (cytotoxin). There have been a number of recent publications describing biological characteristics of toxins A and B (6,7,8,9,10,11,12). However the etiology of PMC does not only depend on colonization of C. difficile toxin producing strains, but other factors affecting the gastrointestinal tract may initiate the disease state, such as antibiotic therapy (13,14,15).

Evidence has developed which indicates that toxins A and B work synergistically to cause PMC (16,17). Lyerly and coworkers demonstrated that large doses of cytotoxin B have little effect when administered intragastrically to hamsters, unless this toxin is administered simultaneous to low non-toxic levels of enterotoxin A, or unless the gut has been subjected to mechanical injury (16). Rolfe and Kim demonstrated that immunization against toxoid B did not protect hamsters from clindamycin induced lethal ileocecolitis, but toxoid A or a combination of toxoid A and B gave protection from lethal ileocecolitis (17). These findings suggest that cytotoxin B is provided an opportunity to work, after enterotoxin A damages tissue.

Toxin A is a large protein which has been demonstrated to elicit a hemorrhagic fluid response in the rabbit intestinal loop assay, cause fluid accumulation in the suckling mouse assay (18,19), exhibit cytotoxic activity on mammalian tissue culture

cells (20), and bind to and agglutinate rabbit erythrocytes (21) The molecular weight of toxin A has been reported by several different groups using non-denaturing gels and gel filtration to be approximately 440,000 to 600,000 (22,23,24). However, elucidation of the quaternary structure of toxin A still requires additional work. Preliminary evidence by Rautenberg and Stender (25) using a 2-dimensional gel system, suggests that toxin A contains two large 230,000 dalton subunits and an unidentified number of smaller subunits of 35,000 dalton. These results do not contradict work done in other laboratories on SDS denaturing gels. Lyster et al. demonstrated using monoclonal antibodies on Western blots of SDS gels the presence of an estimated 300,000 molecular weight band and numerous minor bands (26). Banno et al. also observed a large protein band on denaturing gels with a molecular weight of 190,000 to 200,000, however they did not observe minor bands (27).

Toxin A and toxin B are two different immunologically (27,28) and biochemically distinct proteins (30), however they share biochemical and immunological characteristics in common. The biochemical similarities that have been reported for these two toxins are: 1) they are heat labile at 56°C; 2) they are inactivated at pH 2; 3) they have a high degree of acidic and hydrophobic amino acids and low amounts of sulfur containing amino acids; and 4) they are susceptible to oxidation (22,28,29). Immunological evidence exist which show that toxins A and B share a common epitope. Three types of monoclonal antibodies against C. difficile's toxins have been observed, one type with epitopes for toxin A, one type with epitopes for toxin B, and another type with epitopes common to both toxins (26,30). These immunological results shows that toxin A and B have similar antigenic sites and that these proteins may share a common subunits.

Studies directed toward the molecular genetics or DNA of C. difficile have not been as numerous as those dealing with the pathology or biochemistry of toxins. DNA directed studies on this organism have included: 1) chromosomal location, homology, and transfer of tetracycline, erythromycin and clindamycin resistance determinants (31,32,33,34); 2) Survey and analysis of extrachromosomal elements (35,36); 3) chromosomal restriction endonuclease digestion for typing C. difficile (34,35); 4) cloning of a functional C. difficile promoter in E. coli (39); 5) cloning of C. difficile species-specific antigen in E. coli (40); 6) generation of a DNA hybridization probe for detection of C. difficile (41); and 7) cloning and analysis of toxin determinants (42,43,44,45,46,47,48,). It should be noted that only three of the ten references listed in sections 4 through 7 above on cloning (42,46,47) are in the form of publications, the other references were abstracts presented at the American Society for Microbiology annual meetings. None of these publications (42,46,47) report DNA sequence analysis of C. difficile genes; thus, molecular cloning and analysis of genes in this gram positive bacteria are still in the developmental stages.

2. Technical Objectives

A. Long Range Goals. The major long range objective of this project is to use C. difficile toxin A as a model to add technical information in the area of vaccine biotechnology as it relates to recombinant DNA studies. Recombinant DNA techniques will be used to identify and isolate specific C. difficile toxin A determinants which code for antigenic sites, with the ultimate goal of immunizing laboratory animals with these genetically engineered epitopes. These long range objectives will be accomplished by first sequencing the toxin gene and deducting the amino acid sequence. From the knowledge of the amino acid sequence, epitopes will be predicted. The predicted epitopes will be synthesized using a DNA synthesizer and cloned into the lacZ gene of the lambda gt11 expression vector. This cloning system will allow for rapid selection of specific antibodies that recognize cloned epitopes. Verification of cloned functional epitopes will be accomplished if affinity purified antibodies which specifically bind to the cloned epitopes, bind to a purified toxin A band during Western-blot analysis. A rapid tissue culture assay, utilizing 96-well microtiter plates, will be employed to determine if the affinity purified antibodies specific for the cloned epitopes can protect mammalian cells from the cytotoxic activity of the toxin. After the cloned epitopes have been characterized, the antigenic peptide-beta-galactosidase fusion proteins will be purified using a commercially available anti-beta-galactosidase column. These fusion proteins will be used to immunize mice. The animals will be challenged later with the purified toxin and the toxic bacterium in order to monitor the production of neutralizing antibodies. The above series of experiments represent a unique approach for prediction, identification and purification of antigenic sites, which may be used as a model for development of any subunit vaccine.

B. Immediate Goals. During the first year of this four year project, C. difficile toxin A gene fragments have been cloned, partially sequenced and characterized. During the next year the DNA sequence of this gene will be fully characterized, and epitopes will be predicted.

MATERIALS AND METHODS

1. Affinity Purification of Antibodies

Antibodies specific for the toxin-positive peptide encoded by recombinant lambda gt11 phage particles were affinity purified from toxin A antiserum using the procedure described by Lyon et al. (49) with the following variations. Recombinant phage were plated at a density of approximately 6,000 plaques per plate (150mm diameter). Nitrocellulose filters were overlaid on the agar plates and incubated at 37°C for 16 hours which allowed for binding of antigens. The filters were next removed and suspended overnight in a 1:50 dilution of E. coli adsorbed toxin

A antiserum. After washing the nitrocellulose paper twice in TTBS (0.05% tween 20, 50 mM tris, 150 mM NaCl, pH 8.0) and once in 10 ml saline, specific antibodies which bound to the nitrocellulose filters were eluted by adding 10 ml of glycine buffer per filter (0.2 M glycine, 0.15 M NaCl, pH 2.8) for 10 minutes. Next the nitrocellulose paper was removed from the glycine buffer and the pH of this selected antibody solution was neutralized by adding 8 mg of Tris per ml of eluate.

2. Electrophoresis and Blotting

Non-denaturing polyacrylamide gel electrophoresis (PAGE) of toxin A was performed in a 5 to 15% gradient slab gel at pH 8.3 (50). Gels were stained with Coomassie Blue R-259. Electrophoretic transfer (Western blotting) of proteins from polyacrylamide gels to nitrocellulose paper was performed as described by Towbin et al. (51).

DNA was separated on a 0.8% agarose gel and stained with ethidium bromide (52). Nick translation with [α - 32 P] dCTP and Southern blot hybridizations were performed as described in the nick translation and sure blot hybridization kits provided by Oncor Inc. (Gaithersburg, Maryland U.S.A.).

3. Cytotoxicity Testing

Supernatant from C. difficile cultures, purified or partially purified toxin A, and crude lysates from E. coli Y1090 (obtained from Promega Biotec) infected with recombinant lambda gt11 (52) and induced with isopropyl thio-beta-D galactopyranoside (IPTG) (53), were filter sterilized and cytotoxic activities determined using 3T3 mouse fibroblasts as described previously (35).

4. DNA Sequence Analysis

Sequence analysis of DNA encoding for toxin A was determined using the Sanger chain-termination sequence procedure. Protocols and reagents from the SequenaseTM kit (United States Biochemical Corporation, Cleveland, Ohio) were used for dideoxy sequencing. Nucleotide sequence data was analyzed by an IBM PC-XT computer with programs from International Biotechnologies, Inc., and a Digital Microvax computer using the data base and graphic programs of CageGem.

5. DNA Synthesis

Oligodeoxynucleotide primers were synthesized using beta-cyanoethyl phosphoramidite chemistry in a MilliGen 7500 DNA synthesizer (54). Analysis and purification of oligonucleotides was performed by either separating DNA by PAGE in a 20% gel, or by fractionating DNA on a trityl-specific reverse phase Delta Pak C18 (Waters Inc.) HPLC column. The three column DNA synthesizer and HPLC systems, which are located in our laboratory, have been

obtained since the funding of the Army contract.

6. Restriction Digestion and Cloning

Restriction endonuclease digestion of DNA, and enzymatic manipulation of DNA for cloning were performed as described by suppliers. Standard procedures that were used for isolation and manipulation of DNA for cloning are described in several molecular cloning manuals (55, 56).

RESULTS AND DISCUSSION

In the original proposal we reported preliminary screening for toxin A antigen producing recombinants in a lambda gt11 genomic library of C. difficile DNA. Seven positive clones were identified and reported in this proposal; however, in subsequent studies all but one of the identified positive plaques spontaneously lost the C. difficile DNA inserts. This was evident by a reversion from clear to blue plaques, loss of immunological reactivity with toxin A antiserum, and by analyzes of DNA inserts on agarose gels. Lambda cd19 was the only recombinant plaque stable enough to allow for consistent immunological verification; however, this clone reverts from clear to blue plaques at a frequency of 2 percent. (It should be noted that other genes have been screened for in this library and are stable.)

Verification of the immunological identity of the isolated toxin A gene fragment in lambda cd19 was determined by affinity purifying toxin A antibodies specific for lambda cd19 gene product, and using these selected antibodies to probe a Western blot of purified toxin A (fig. 1). E. coli lysates generated from infecting Y1090 with lambda cd19 phage particles and induced with IPTG, were negative for cytotoxic activity on 3T3 mammalian tissue culture cells.

The EcoR1 cloning site in lambda gt11 is contained within a 2.08 kb SacI-KpnI fragment (53); therefore, lambda cd19 DNA was double digested with SacI-KpnI. This 2.08 kb SacI-KpnI fragment was increased in size in lambda cd19 to 2.40 kb, thereby demonstrating the presence of a 0.3 kb TagI insert (fig. 2). (Note, the genomic library was generated with TagI.) A 0.3 kb C. difficile DNA insert in lambda cd19 was also demonstrated by hybridizing [alpha-³²P] nick translated lambda cd19 DNA to a C. difficile TagI chromosomal digest (fig. 3). The [alpha-³²P] labeled cd19 probe also hybridized to a 4.5 kb fragment in a PstI chromosomal digestion of C. difficile, and a 16 kb fragment in a HindIII digestion (fig. 3).

The toxin A gene fragment in lambda cd19 was not recoverable from EcoR1 digestion of this DNA, even though this insert was ligated into the EcoR1 site of lambda gt11. To determine why this DNA insert did not digest out with EcoR1, the SacI-KpnI

fragment was subcloned into M13 (mp18 and mp19) and mapped. Upon simultaneous exposure to EcoR1 and Kpn1 two fragments approximately 1.02 kb and 1.41 kb were produced (fig. 4). The 1.41 kb fragment was generated because an EcoR1 site is located in the multiple cloning region of the M13 vector (this site is contiguous with Sac1). The 1.02 and 1.41 kb fragments were also present with a Sac1-EcoR1-Kpn1 triple digestion of the hybrid DNA. However a double digestion with Sac1-EcoR1 generated a single fragment of 1.41 kb (fig. 4). A restriction map created from these experiments revealed that a single EcoR1 site adjacent to the Sac1 site in lambda cd19 was destroyed or some how protected from digestion following initial cloning (fig. 5).

Attempts were made to sequence the toxin A DNA in the 2.4 kb Kpn1-Sac1 fragment cloned in M13 by using a synthesized 15-mer oligonucleotide which hybridizes to lambda gt11 sequence adjacent to the toxin A insert. A search of GenBank using the IBI software for homology between the primer and M13 suggested that this primer should not bind to M13. However results of sequences generated in these experiments demonstrated that the primer was selectively priming non-targeted sequences. Therefore, the 1.4 kb EcoR1-Sac1 fragment containing the 0.3 kb C. difficile gene was subcloned in M13mp18 and M13mp19 for sequencing. Due to the presence of 1.02 kb of lambda gt11 lacZ DNA preceding C. difficile insert within M13mp18, it was sequenced with a reverse primer, whereas the insert subcloned in M13mp19 was sequenced using M13 universal primer. The DNA sequence and predicted open reading frame of the toxin DNA fragment is shown in figure 6. An hydropathy plot of the open reading frame is given in figure 7, and regions that will be considered in future studies for antigenicity have been indicated.

The 16 kb HindIII fragment identified in the chromosomal digest of C. difficile strain 10463 is being used to clone for the complete toxin A gene or DNA which codes for a complete subunit. DNA surrounding this 16 kb HindIII fragment has been isolated using the Ultrahydrogel DNA HPLC column (Waters Inc.), dephosphorlated, and ligated in the replacement vector lambda 2001. This population of recombinants are being screened with a ³²P synthetic DNA probe generated from base pair 38 to 80 (fig. 6). We are currently conducting these experiments. In a recent publication by Wren and coworkers (46) a 14 kb BamH1 fragment was cloned into the EMBL3 replacement vector. This fragment coded for a 235 kDa protein with toxic activity. We will also clone and characterize this fragment.

RECOMMENDATIONS AND CONCLUSIONS

One of the main objectives of this contract is to develop a system for testing epitopes using the expression vector lambda gt11, which includes reporting potential problems and solutions to these problems. From our experience of cloning toxin A and as

well as toxin B gene fragments in lambda gt11, and from personal communications with other investigators, we have identified non-published common problems encountered when using this cloning system. Due to the vector:insert DNA ratio, it is extremely difficult to visualize on an ethidium bromide agarose gel, inserts that are under several hundred base pairs. When foreign DNA inserts are placed in lambda gt11 the EcoRI insertion sites are often lost. To avoid missing small inserts or clones that have lost the EcoRI sites, we recommend routinely screening for inserts in lambda gt11 hybrids by double digestion with SacI-KpnI as described in the Results and Discussion.

In conclusion we have cloned, sequenced and partially characterized a toxin A DNA fragment, and initiated work toward cloning the full length toxin gene. During the next year of work we plan to obtain the complete sequence for the toxin gene, predict epitopes, and begin synthesis of these predicted epitopes.

REFERENCES

1. Hall, I.C., E. O'Toole. 1935. Am. J. Dis. Child. 44:390.
2. Barlett, J.S., T.W. Chang, N.S. Taylor, A.B. Onderdonk. 1979. Rev. Infect. Dis. 1:380.
3. Fekety, R. Prevention and treatment of antibiotic-associated colitis. pp. 276. American Society for Microbiology, Washington, D.C.
4. Medline, A., D.H. Skin, N.M. Medline. 1976. Human Pathol. 7:693.
5. Totten, M.A., J.A. Gregg, Fremont-Smith, M. Legg. 1978. Am. J. Gastroenterol. 69:311.
6. Borriello, S.P., J.M. Ketley, T.J. Mitchell, F.E. Barclay, A.R. Welch, A.B. Price, J. Stephen. 1987. J. Med. Microbiol. 24:53.
7. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbiol. 23:211.
8. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbiol. 23:205.
9. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbiol. 23:199.
10. Ketley, J.M., T.J. Mitchell, D.C.A. Candy, D.W. Burdon, J. Stephen. 1987. J. Med. Microbiol. 24:41.
11. Triadafilopoulos, G., C. Pothoulakis, M. O'Brien, J.T. LaMont. 1987. Gastroenterology. 93:273.
12. Lima, A.A.M., D.M. Lyerly, T.D. Wilkins, D.J. Innes, R.L. Guerrant. 1988. Infect. Immun. 56:582.
13. George, W.L., V.L. Sutter, S.M. Finegold. 1978. Curr. Microbiol. 1:55.
14. Binner, E.J., W.H. Tellman. 1970. Am. Med. J. Gastroenterol. 34:55.
15. Bartlett, J.G., A.B. Onderdonk, R.L. Cisneron, D.L. Ksaper. 1977. J. Infect. Dis. 136:701.
16. Lyerly, D.M., K.Ek Saum, D. K. MacDonald, T. D. Wilkins.

1985. *Infect. Immun.* 47:349.
17. Rolfe, R.D., P. Kim. 1987. *Amer. Society Microbiol. Meeting. Abstract # B-222.*
 18. Lyerly, D., M. D. Roberts, C. Phelps, T. D. Wilkins. 1986. *FEMS Microbio. Let.* 33:31.
 19. Taylor, N.S., G.M. Thorne, J.G. Barlett. 1981. *Infect. Immun.* 34:1036.
 20. Florin, L., M. Theslan. 1981. *Infect. Immun.* 33:66.
 21. Krivan, H.C., G.F. Clark, D.F. Smith, T.C. Wilkins. 1986. *Infect. Immun.* 53:573.
 22. Sullivan, N.M., S. Pellett, T.D. Wilkins. 1982. *Infect. Immun.* 35:1032.
 23. Banno, Y., T. Kobayashi, K. Watanabe, K. Ueno, Y. Nozawa. 1981. *Biochem. Interm.* 6:629.
 24. Aronsson, B., R. Mollby, C.E. Nord. 1982. *Scand. J. Infect. Dis. Suppl.* 35:53.
 25. Rautenberg, P., F. Stender. 1986. *FEMS Microbiol.* 37:1
 26. Lyerly, D.M., C. Phelps, J. Toth, T. D. Wilkins. 1986. *Infect. Immun.* 54:70.
 27. Banno, Y., T. Kobayashi, H. Kono, K. Watanabe, K. Ueno, Y. Nozawa. 1984. *Rev. Infect. Dis.* 6(Suppl. 1):11.
 28. Stephen, J., S.C. Redmond, T.J. Ketley, C.A. Candy, D.W. Burdon, R. Daniel. 1984. *Biochem. Soc. Trans.* 12:194.
 29. Lyerly, D., M. D. Roberts, C. Phelps, T. D. Wilkins. 1986. *FEMS Microbio. Let.* 33:31.
 30. Rolfe, R., J. Szkudlarek, K. Follis, C. Faust. 1986. *American Society Microbiol Meeting, Abstracts:# B62*
 31. Hachler, H. F.H. Kayser, B. Berger-Bachi. 1987. *Antimicrob. Agents Chemother.* 31:1033.
 32. Hachler, H., B. Berger-Bachi, F.H. Kayser. 1987. *Antimicrob. Agents Chemother.* 31:1039.
 33. Smith, C.J., S.M. Markowitz, F.L. Macrina. 1981. *Antimicrob. Agents Chemother.* 19:997.
 34. Ionesco, H. 1980. *Ann. Microbiol. (Inst. Pasteur).* 131:171.
 35. Muldrow, L.L., E.R. Archibold, O.L. Nunez-Montiel, R.J. Sheehy. 1982. 16:637.
 36. Neher, J. B., J.M. Libby. 1985. *American Society Microbiol. Meeting, Abstract:# B124.*
 37. Kuijper, E.J., J.H. Oudbier, W.N.H.M. Stuifbergen, a. Jansz, H.C. Zanen. 1987. *J. Clin. Microbiol.* 25:751.
 38. Peerbooms, P.G.H., P. Kuijt, D.M. MaClaren. 1987. *J. Clin. Pathol.* 49:771.
 39. Dailey, D.C., R.H. Schloemer. 1987. *American Society Microbiol. Meeting, Abstract:# D36.*
 40. Wren, B.W., C.C. Clayton, P.P. Mullany, S. Tabagchali. 1988. *American Society Microbiol. Meeting, Abstract:# D87.*
 41. Fasching, C., L. Perterson, J. Moody, C. Clabots. *American Society Microbiol. Meeting, Abstract:# D87.*
 42. Muldrow, L.L., G. Ibeanu, N.I.Lee, N.K. Bose, J. Johnson. 1987. *FEBS.* 213:249.
 43. Price, S.B., J.L. Johnson. 1986. *American Society Microbiol. Meeting, Abstract:# D11*
 44. Dove, C.H., S.B. Price, C.J. Phelps, J.L. Johnson. 1987.

- American Society Microbiol Meeting, Abstracts:# D88.
45. Muldrow, L.L., G. Ibeanu, N.I.Lee, N.K. Bose, J. Johnson. 1988. American Society Microbiol Meeting, Abstracts:# B49. Also submitted for publication.
 46. Wren, B.W., C.L. Clayton, P.P. Mullany, S. Tabaqchali. 1988. FEB 225:82.
 47. Price, S.B., C.J. Phelps, T.D. Wilkins, J.L. Johnson. 1988. Curr. Microbiol. 16:55.
 48. Edwards, M. 1987. Am. Biotech. Lab. Nov\Dec:38.
 49. Lyon, J.A., R.H. Geller, J.D. Haynes, J.D. Chulay, J.L. Weber. 1986. Proc. Natl. Acad. Sci. USA 83:2989.
 50. Laemmli, U.K. 1970. Nature. 227:680.
 51. Towbin, H., T. Stahelin, J. Gordon. 1979. Proc. Natl. Acad. Sci. USA. 76:4350.
 52. Maniatis, T., E.F. Fritsch, J. Sambrook. 1982. Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Hobor, New York.
 53. Young, R.A., R.W. Davis. 1983. Proc. Natl. Acad. Sci. USA 80:1194.
 54. Urdea, M.S., L. Ku, T. Horn, Y.G. Gee, B.D. Warner. 1985. Nucl. Acids Res. 16:257.
 55. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman, K. Struhl. 1987. Current Protocols in Molecular Biology. John Wiley & Sons, New York.
 56. Davis, L.G., M.D. Dibner, J.F. Battey. 1986. Basic Methods In Molecular Biology. Elsevier, New York.



Figure 1. Purity of toxin A, and confirmation of cloned toxin determinants. PAGE and Western blot analysis were performed as described in materials and methods. Lanes: (1) PAGE of 6 µg purified toxin A. (2) Western blot of toxin A using control toxin A antiserum, 1:200 dilution. (3) Western blot of toxin A with selected antibodies from lambda gt11 control plaques. (4) Western blot of toxin A with antibodies selected from lambda cd19.




Figure 2. Restriction digestion of lambda gt11 and lambda cd19. Lambda gt11 (lane 1) and lambda cd19 (lane 3) were double digested with SacI and KpnI as described by supplier. The band immediately above the 2.4 kb fragment in lane 3 represents incomplete digestion of the 2.4 kb fragment and the lower migrating 1.51 kb fragment. Lane 2 contains the molecular weight standard HindIII digested lambda DNA (BRL Inc., Gaithersburg, Maryland USA).




Figure 3. Southern hybridization of restriction digested *C. difficile* chromosomal DNA with [α - 32 P] dCTP labeled lambda cd19. *C. difficile* chromosomal DNA was digested with TagI, lane 1; HindIII, lane 2; and PstI, lane 3.




Figure 4. Restriction digestion of cdmp19. Lane 1 was digested with SacI, EcoRI and KpnI; lane 2 with SacI and EcoRI; and lane 3 with EcoRI and KpnI. A molecular weight marker for the standard HindIII digested lambda DNA is given on the right.




Figure 5. Restriction map of the Kpn1-Sac1 DNA fragment from lambda cd19 that was subcloned into M13. Thick bar represents toxin A DNA, (+) designates the damaged EcoR1 site.

	10		20		30		40		50		60								
	*		*		*		*		*		*								
CGG	GCT	CCA	GGA	GTC	GTC	GCC	ACC	AAT	CCC	CAT	ATG	GAA	ACC	GTC	GAT	ATT	CAG	CCA	TGT
Arg	Ala	Pro	Gly	Val	Val	Ala	Thr	Asn	Pro	His	Met	Glu	Thr	Val	Asp	Ile	Gln	Pro	Cys
	70		80		90		100		110		120								
	*		*		*		*		*		*								
GCC	TTC	TTC	CGC	GTG	CAG	CAG	ATG	GCG	ATG	GCT	GGT	TTC	CAT	CAG	TTG	CTG	TTG	ACT	GTA
Ala	Phe	Phe	Arg	Val	Gln	Gln	Met	Ala	Met	Ala	Gly	Phe	His	Gln	Leu	Leu	Leu	Thr	Val
	130		140		150		160		170		180								
	*		*		*		*		*		*								
GCG	GCT	GAT	GTT	GAA	CTG	GAA	GTC	GCC	GCh	CCA	CTG	GTG	TGG	GCC	ATA	ATT	CAA	TTC	GCh
Ala	Ala	Asp	Val	Glu	Leu	Glu	Val	Ala	Ala	Pro	Leu	Val	Trp	Ala	Ile	Ile	Gln	Phe	Ala
	190		200		210		220		230		240								
	*		*		*		*		*		*								
CnT	CCC	GCA	GGC	CAG	ACC	GAA	AAC	GCT	CGG	GAA	GAC	GTA	CnG	GTA	TAC	ATG	TCT	GAC	AAT
XXX	Pro	Ala	Gly	Gln	Thr	Glu	Asn	Ala	Arg	Glu	Asp	Val	XXX	Val	Tyr	Met	Ser	Asp	Asn
	250		260		270		280		290		300								
	*		*		*		*		*		*								
GGC	AGA	TCC	AGC	GTC	AAA	CAG	CGC	AGT	AAG	GCG	TCG	GAT	AGT	TTC	TTG	CGC	CTA	ATC	GAG
Gly	Arg	Ser	Ser	Val	Lys	Gln	Arg	Ser	Lys	Ala	Ser	Asp	Ser	Phe	Leu	Arg	Leu	Ile	Glu

CCA GGT TAC
Pro Gly Tyr

Figure 6. DNA and amino acid sequence of toxin A gene fragment.

